{"entity":{"id":"idea-fund-global-cancer-fund","kind":"idea","name":"A Global Fund for cancer care in low- and middle-income countries","aka":[],"tldr":"Copy the model that transformed HIV, TB and malaria care: a pooled international fund that pays for radiotherapy machines, pathology labs and essential cancer medicines where there are none.","summary":"A replenishment-based multilateral financing facility, governed with recipient countries, that funds radiotherapy capacity (building on IAEA Rays of Hope), pathology and diagnostic networks, pooled procurement of essential oncology medicines at negotiated prices, and workforce training. Allocation would follow burden and readiness formulas. Cancer now kills more people in LMICs than HIV, TB and malaria combined, but has no comparable financing vehicle; philanthropic and bilateral efforts are fragmented.","asOf":"2026-09-08","links":[{"label":"IAEA Rays of Hope","url":"https://www.iaea.org/services/rays-of-hope"},{"label":"The Global Fund","url":"https://www.theglobalfund.org/"}],"tags":[],"related":["idea-fund-lmic-burden-match","idea-fund-lmic-radiotherapy-finance"],"cancers":["cervical","breast-hr-positive","hcc"],"sections":[],"technologies":["imrt-igrt","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc","tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-funding-allocation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A pooled fund disbursing over a billion dollars a year raises radiotherapy capacity in recipient countries by at least 50% and essential-medicine availability above 80% within five years, with measurable improvement in stage-adjusted survival for cervical and breast cancer within ten.","rationale":"The Global Fund and Gavi show that pooled procurement, predictable financing and country-led allocation can deliver complex health interventions at scale; radiotherapy and generic chemotherapy are cost-effective by any standard, and price falls of 90% for HIV drugs followed pooled purchasing.","test":"A five-country pilot with a fund of a few hundred million dollars, pre-registered indicators for capacity, availability and stage-adjusted survival, compared with matched non-participating countries.","maturity":"speculative","actor":"policy","cost":"large","horizonYears":5},"route":"/ideas/idea-fund-global-cancer-fund/","neighbours":{"idea":[{"id":"idea-fund-lmic-radiotherapy-finance","kind":"idea","name":"Blended finance and a low-cost linac to close the global radiotherapy gap","route":"/ideas/idea-fund-lmic-radiotherapy-finance/"},{"id":"idea-fund-lmic-burden-match","kind":"idea","name":"Burden-matched funding for trials led in low- and middle-income countries","route":"/ideas/idea-fund-lmic-burden-match/"},{"id":"idea-fund-public-option-generic-oncology","kind":"idea","name":"Public-option manufacturing for essential generic cancer drugs in shortage","route":"/ideas/idea-fund-public-option-generic-oncology/"}],"cancer":[{"id":"cervical","kind":"cancer","name":"Cervical cancer","route":"/cancers/cervical/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"}],"technology":[{"id":"brachytherapy","kind":"technology","name":"Brachytherapy","route":"/technologies/brachytherapy/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"institution":[{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","route":"/institutions/iarc/"},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","route":"/institutions/tata-memorial/"}],"bottleneck":[{"id":"b-funding-allocation","kind":"bottleneck","name":"Funding follows fashion, not burden","route":"/bottlenecks/b-funding-allocation/"},{"id":"b-global-access","kind":"bottleneck","name":"Most of the world has almost no cancer care","route":"/bottlenecks/b-global-access/"}],"roadmap":[{"id":"global-access-roadmap","kind":"roadmap","name":"Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation","route":"/roadmaps/global-access-roadmap/"}]}}